Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 32803 | Peak area normalized | male | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 40762 | Peak area normalized | female | normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 42563 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 44347 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 44761 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 45245 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 45494 | Peak area normalized | female | normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 46680 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 47363 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 48850 | Peak area normalized | male | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 51151 | Peak area normalized | male | pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 53433 | Peak area normalized | male | pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 58179 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+H)+ | 96592 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 7775 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 10068 | Peak area normalized | male | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 10930 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 11865 | Peak area normalized | female | normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 13387 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 13689 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 14163 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 14621 | Peak area normalized | female | normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 16017 | Peak area normalized | male | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 17122 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 17874 | Peak area normalized | male | pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 18230 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 19442 | Peak area normalized | male | pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | LYSINE (M+NA)+ | 29464 | Peak area normalized | female | diabetic | no neuropathy |